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INTRODUCTION
Plasmablastic lymphoma (PBL) is a lymphoproliferative
disorder that is considered a type of diffuse large B-cell non-
Hodgkin’s lymphoma (NHL); it is a morphologic variant by
the currently proposed World Health Organization (WHO)
classification system (1). Due to its recent recognition as a
unique disease entity, it has only been partially characterized,
primarily on the basis of sporadic case reports (2-6). To date,
PBLs have been found frequently in patients infected with
the human immunodeficiency virus (HIV) (2, 3); these pati-
ents characteristically present with extranodal disease involv-
ing the oral cavity. In this report, we describe an unusual case
of PBL that presented with a large mass originating from the
jejunum in a HIV-seronegative patient.
CASE REPORT
A 60-yr-old man presented to the emergency department
with complaints of dyspnea and dizziness. Two months ago,
he underwent an upper endoscopy, colonoscopy and cardiac
single photon emission computed tomography (CT) in another
hospital for anemia and exertional dyspnea, and the results
were all within normal limits. The patient also underwent a
biopsy of a chest wall mass and a fine needle aspiration of a
cervical lymphadenopathy that was incidentally detected by
the CT of the chest. The results of the biopsy and fine needle
aspiration were non-specific, and a follow-up appointment
was made after 3 months. However, his exertional dyspnea
progressively worsened over the past 1 month. On admission,
he reported a weight loss of 7 kg during the last two months
and melena five days ago. There were no conditions associat-
ed with immunosuppression. On physical examination, the
patient was found to have a 2.5 cm ovoid mass in the sub-
mandibular area; similar but smaller lesions were present on
the forehead, chest wall and right vestibule of the oral cavi-
ty. There were a right supraclavicular lymphadenopathy and
bilateral axillary lymphadenopathies without tenderness. 
The laboratory data on admission included a white blood
cell count of 6,800/mL (72% polymorphonuclear leucocytes,
18% lymphocytes and 8% monocytes), a hemoglobin con-
centration of 6.2 g/dL and a platelet count of 397,000/mL.
The serum iron was 13 mL/dL, total iron-binding capacity
394 mL/dL and the serum ferritin was 5.4 ng/mL. The bio-
chemical analysis of the blood for hepatic and renal function,
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A Case Report with Plasmablastic Lymphoma of the Jejunum
Plasmablastic lymphoma (PBL) is a recently identified entity that is considered to
be a type of diffuse large B-cell lymphoma with a unique immunophenotype and a
predilection for the oral cavity of patients with the human immunodeficiency virus
(HIV). Although its clinical features may help in the differential diagnosis, an extra-
oral location in a patient without HIV makes it more difficult to suspect clinically. This
case report is the first to describe a patient with PBL originating from the jejunum in
a 60-yr-old, HIV-seronegative man. Computed tomography of the face, chest and
abdomen showed about a 9.4×9.0 cm mass of the proximal jejunum, multiple mass-
es in the musculoskeletal soft tissue, and multiple lymphadenopathies. The histo-
logical examinations demonstrated a large cell lymphoma with plasmablastic differ-
entiation. The neoplastic cells were diffusely positive for MUM1, epithelial membrane
antigen and lambda light chains, and focally positive for CD79a; but negative for
CD3, CD20, CD30, CD34, CD45RO, CD56, CD99, and CD117. The proliferation
index by Ki-67 immunohistochemistry was approximately 70%. These findings were
compatible with the diagnosis of PBL. The findings in this case suggest that PBL
should be included in the differential diagnosis of a small bowel mass even in a
HIV-negative patient.
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lactate dehydrogenase and the urine analysis were all within
normal limits. The serum CEA and CA 19-9 were normal,
and the tests for HIV, which were performed at admission
and 3 months later, were all negative. 
The conventional esophagogastroduodenoscopy showed
normal esophagus, stomach and duodenum; however, a fri-
able ulcerofungating mass was noted over 10 cm segment
in the proximal jejunum (Fig. 1). The findings of multiple
endoscopic biopsies revealed diffuse infiltration of neoplas-
tic lymphoid cells with plasmablastic differentiation. CT of
the abdomen showed a 9.4×9.0 cm lobulated mass with
enhancement in the proximal jejunum (Fig. 2A) as well as
multiple enhancing nodules in the greater omentum, trans-
verse mesocolon, and left retroperitoneal space. The double
contrast small bowel series showed a growing exophytic mass
with central ulcers in the proximal jejunum (Fig. 2B), how-
ever, the other small bowel loops were normal. CT of the face
and chest showed about a 2.3 cm ovoid mass in the right sub-
mandibule, multiple oval or round masses in the musculos-
keletal soft tissue (sternum, costal cartilage, both ribs, clav-
icles, scapulas, chest wall, right sternocleidomastoid muscle,
pectoralis major muscle, right supraspinatus muscle, and left
retroperitoneum) and multiple lymphadenopathies (Fig. 3).
Excisional biopsies of the masses from the oral cavity and the
forehead and of the supraclavicular lymphadenopathy were
performed, and its findings revealed a monotonous prolifera-
tion of plasmablastic cells with abundant cytoplasm and round
nuclei (Fig. 4A). The neoplastic cells were diffusely positive
for MUM1, epithelial membrane antigen (EMA) and lamb-
da light chains (Fig. 4B, C) and focally positive for CD79a;
however, they were negative for CD3, CD20, CD30, CD34,
CD45RO, CD56, CD99, CD117, and CD138. The prolif-
eration index with Ki-67 immunohistochemistry using the
MIB-1 monoclonal antibody was approximately 70% (Fig.
4D). In situ hybridization for the Epstein-Barr virus was neg-
ative. A staging bone marrow aspirate and biopsy was free
of lymphoma. The serum protein electrophoresis showed a
lambda type monoclonal gammopathy. Based on these find-
ings, the patient was diagnosed stage IV PBL.
The patient was transferred to the oncology service and
treated with cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) chemotherapy. There was an excel-
lent initial response with near complete resolution of all lesions
with six cycles of CHOP. Eight months later, however, the
Fig. 1. Endoscopic finding. The conventional esophagogastro-
duodenoscopy showed a friable ulcerofungating mass over 10
cm segment.
Fig. 2. Radiologic images of a jejunal mass. (A) Abdominal CT shows a 9.4×9.0 cm enhancing lobulated mass (arrow) originating from
the proximal jejunum. (B) Small bowel series shows a growing exophytic mass (arrows) with central ulcers in the proximal jejunum. The
adjacent bowel loops were displaced; however, the other small bowel loops were normal.
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disease recurred with a newly developed mesenteric mass.
Autologous peripheral blood stem cell transplantation was
planned, and salvage chemotherapy was provided with eto-
poside, methylprednisolone, high-dose cytarabine, and cis-
platin (ESHAP). However, the disease progressed and loco-
regional radiation therapy was given for a left forehead mass
and pathologic fracture of the left clavicle. The patient is still
alive for 24 months after the initial diagnosis. 
DISCUSSION
PBL of the oral cavity was first described in 1997 (2); it has
been recognized as a distinct entity, a subtype of diffuse large
B-cell lymphoma, by the WHO classification of lymphopro-
liferative disorders (1). Since first described, more than 150
patients with this disease have been reported (7). PBLs have
been strongly associated with immunodeficiency, most par-
ticularly in patients with the HIV infection (7). Therefore,
this case is very unusual in that the PBL presented as a large
jejunal mass in a HIV-seronegative patient. 
The most notable feature of PBL is its predilection for the
oral cavity and most patients with PBL present with prima-
ry oral lesions (2). The disease sites during progression are
frequently widespread and have reportedly involved the cen-
tral nervous system, abdominal viscera and musculoskeletal
soft tissue (2, 7). Recently, the primary sites have been more
frequently reported outside of the oral cavity or concurrent
with oral involvement (4, 5). Over one-third of all cases with
PBL were first noted at extra-oral locations, and the gastroin-
testinal tract has been observed to be the most common extra-
oral site (10.6%) (7). Although the clinical features of PBL,
including its association with HIV, male gender and predilec-
tion for the oral cavity, may help in the differential diagno-
sis, cases that present with extra-oral locations and without
HIV are less likely to be suspected clinically, as this case illus-
trates. 
The histological appearance of PBL is usually monomor-
phic with a diffuse lymphoid infiltrate and a cohesive growth
pattern. The neoplastic cells resemble plasmablasts with eccen-
tric round or oval nuclei that have fine chromatin (2). The
cytoplasm of the cells is abundant and appears deeply baso-
philic on Giemsa staining (2). PBL usually has a character-
istic immunophenotype; it is negative for the typical B-cell
Fig. 3. CT imaging showing multiple areas of lymphoma infiltration. Arrows indicate lymphoma lesions. (A) About a 2.3 cm ovoid mass in
the right submandibular space. (B, C) Multiple oval or round masses in the musculoskeletal soft tissue in the chest wall and pectoralis
major muscle. (D) Chest CT shows a right supraclavicular lymphadenopathy. 
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antigens (e.g., CD20 and CD45) and positive for plasma cell
markers such as MUM1, EMA, CD38, and CD138 (2, 7-9).
PBLs invariably have restricted immunoglobulin light chains
in the cytoplasm (positive staining for lambda, but not kappa),
as in our case. All PBLs characteristically display a high rate
of mitotic activity by the Ki-67 proliferation index (2), which
is also consistent with our findings. Although not specific,
the combination of these histopathological features is char-
acteristic of PBL; therefore, immunophenotypic studies must
be performed to confirm the diagnosis. PBL should be differ-
entiated from neoplastic plasma cells and other varieties of
NHL. Unlike PBL, a plasmacytoma typically consists of mature
plasma cells without a high rate of mitotic activity. Diffuse
large B-cell lymphomas nearly always express CD20, CD45-
RA and CD79a; and Burkitt’s lymphomas express CD20,
CD45RA and CD79a, as well as the membrane-bound IgM
heavy chain isotype, all of which are not typical for PBL (2, 7). 
The general prognosis of PBL is very poor with a rapidly
progressive clinical course (2, 7); half of the original 16 pati-
ents died within one year (2). An optimal chemotherapy reg-
imen has not been established; the initial therapy has includ-
ed administration of multi-agent systemic chemotherapy or,
alternatively, local irradiation alone (2). Despite the advanced
stage at presentation, this patient initially achieved a good
response to the lymphoma-specific combination chemother-
apy and is still alive for 24 months after the initial diagnosis. 
In conclusion, the clinical features of PBL including its
association with HIV, male gender and predilection for the
oral cavity, may help in the differential diagnosis, however,
an extra-oral location in a HIV-seronegative patient makes
it more difficult to suspect clinically. This case highlights an
unusual presentation of PBL with a large small bowel mass
in a HIV-seronegative patient. Hence, PBL may be includ-
ed in the differential diagnosis of a small bowel mass even
in HIV-seronegative individuals. 
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